Cargando…

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland

IMPORTANCE: Biologics account for a substantial proportion of health care expenditures. Their costs have been projected to reach US $452 billion in global spending by 2022. Given recent expiration of patent protection of biologics, a shift toward greater follow-on competition among biosimilars would...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carl, David L., Laube, Yannic, Serra-Burriel, Miquel, Naci, Huseyin, Ludwig, Wolf-Dieter, Vokinger, Kerstin N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719051/ https://www.ncbi.nlm.nih.gov/pubmed/36459139 http://dx.doi.org/10.1001/jamanetworkopen.2022.44670

Ejemplares similares

The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study
por: Serra-Burriel, Miquel, et al.
Publicado: (2023)

Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
por: Carl, David L, et al.
Publicado: (2021)

Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study
por: Vokinger, Kerstin N, et al.
Publicado: (2023)

Availability of New Medicines in the US and Germany From 2004 to 2018
por: Blankart, Katharina, et al.
Publicado: (2022)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2019)

Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis
por: Luo, Xingxian, et al.
Publicado: (2023)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population
por: Kozlowski, Steven, et al.
Publicado: (2022)

Drivers of Acceptance of COVID-19 Proximity Tracing Apps in Switzerland: Panel Survey Analysis
por: von Wyl, Viktor, et al.
Publicado: (2021)

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
por: Luukkanen, Saana V., et al.
Publicado: (2022)

The Baths of Germany, France, and Switzerland
Publicado: (1857)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition
por: Dickson, Sean R., et al.
Publicado: (2021)

The price of nicotine dependence: A comparison of the cost of nicotine across products in Switzerland, Germany, USA, Sweden, France and the UK, in 2019
por: Jakob, Julian, et al.
Publicado: (2022)

Production costs and potential prices for biosimilars of human insulin and insulin analogues
por: Gotham, Dzintars, et al.
Publicado: (2018)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

Biosimilar Uptake: The Importance of Healthcare Provider Education
por: Oskouei, Sonia Tadjalli, et al.
Publicado: (2021)

Biosimilar medicines uptake: The role of the clinical pharmacist
por: Okoro, Roland Nnaemeka
Publicado: (2021)

Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars
por: Azuz, Samuel, et al.
Publicado: (2021)

Who's who in technology: Austria, Germany, Switzerland
por: Groeg, Otto J
Publicado: (1979)

Who's who in technology: Austria, Germany, Switzerland
por: Groeg, Otto J
Publicado: (1979)

Physicians’ perceptions of the uptake of biosimilars: a systematic review
por: Sarnola, Kati, et al.
Publicado: (2020)

Comparison of food and beverage products’ availability, variety, price and quality in German and US supermarkets
por: Stroebele-Benschop, Nanette, et al.
Publicado: (2020)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
por: Barszczewska, Olga, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Benefit assessment in Germany: implications for price discounts
por: Theidel, Ulrike, et al.
Publicado: (2016)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017)

Biosimilars 101: considerations for U.S. oncologists in clinical practice
por: Camacho, Luis H, et al.
Publicado: (2014)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
por: Rahalkar, Hasumati, et al.
Publicado: (2021)

Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany
por: Blankart, Katharina E., et al.
Publicado: (2020)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Motivations and Limits for COVID-19 Policy Compliance in Germany and Switzerland
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

Biosimilar uptake by British local formularies: a cross sectional study
por: Alnahar, Saja, et al.
Publicado: (2017)

Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data
por: McClean, Alison R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_647dsrhnbgk2n5rsbb9n32t849